Skip to main content
Premium Trial:

Request an Annual Quote

CHI Says Toxicogenomics Can Quash Drug-Development Flops

NEW YORK, April 16 - Toxicogenomics is the key to eliminating drug-development failures, according to a report from the Cambridge Healthtech Institute.


The forthcoming study heralds toxicogenomics as a crucial part of the future of drug development. This technology, according to the report, promises faster, more accurate, and more efficient screening and elimination of potential compounds, and substantially reduced R&D costs.


It describes public and private efforts to advance toxicogenomic studies, including both environmental and pharmaceutical applications of this technology. The report also includes profiles of several dozen toxicogenomic companies and an analysis of their deals.


Cambridge Healthtech generates reports and hosts conferences about the application of genomic technologies in industry.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.